Anavex completes clinical conduct of two blarcamesine pharmacology studies
AVXL•Anavex Life Sciences completed two blarcamesine clinical pharmacology studies intended to support its FDA-focused Alzheimer’s disease program. Preliminary findings showed no serious adverse events, while full safety and pharmacokinetic analyses remain ongoing.
1. Studies completed
Anavex Life Sciences completed two clinical pharmacology studies of blarcamesine intended to support its FDA-focused Alzheimer’s disease development program. Preliminary findings showed no serious adverse events; full safety and pharmacokinetic analyses are ongoing.
2. Other trial updates
The FDA cleared blarcamesine’s Fragile X syndrome trial application, with start-up activities underway. An FDA meeting in November will address adding pediatric participants to the Phase 3 Rett syndrome trial, which currently covers adults.
